[#item_full_content] The DEA’s upcoming hearing could redefine the cannabis landscape, impacting everything from banking access to tax burdens. Investors must navigate the complexities of potential Schedule III rescheduling and the looming hemp-derived THC debate. What does this mean for your portfolio? Explore now. 
Read More
